• Immatics N.V. reported past second quarter 2026 results showing a net loss of €62.49 million, narrower than the prior year, while the six‑month net loss increased to €120.31 million.
• The company’s quarterly loss per share improved year on year, even as the cumulative loss for the first half of 2026 edged higher.
• Next, we will examine how Immatics’ narrower quarterly loss per share shapes its investment narrative in light of these mixed results.

Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

What Is Immatics' Investment Narrative?

To own Immatics today, you have to believe its PRAME‑focused cell therapies and bispecifics can eventually translate strong early oncology data into a sustainable business, despite ongoing losses. The latest quarter reinforces that tension: the net loss remains heavy at €62.49 million, yet the narrower quarterly loss per share hints at some early operating discipline after a very tough 2025. For near term catalysts, the story still centers on progress in the SUPRAME Phase 3 trial for anzu‑cel, updates across the broader PRAME franchise, and any new partnerships that could help fund development without excessive dilution. The new results do not materially change those drivers, but they sharpen the key risk already in focus: Immatics is unprofitable, trades at a rich sales multiple, and still needs substantial capital to reach the next clinical inflection points.

However, one concern around how Immatics might fund its ambitions deserves closer attention. Our valuation report unveils the possibility Immatics' shares may be trading at a premium.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span from well under €1 to €17.80, underscoring how far apart expectations sit. Set against Immatics’ persistent losses and premium sales multiple, that spread highlights why it can help to review several contrasting views before deciding how the PRAME story fits in your portfolio.

Explore 3 other fair value estimates on Immatics - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Immatics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Immatics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immatics' overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.